Institutional members access full text with Ovid®

Share this article on:

Angiotensin-(1–9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis

Ocaranza, Maria Paza; Moya, Jackelinea; Barrientos, Victorb,c; Alzamora, Rodrigob,c; Hevia, Danielb,c; Morales, Cristobala,d; Pinto, Melissaa; Escudero, Nicolása; García, Lorenad; Novoa, Ulisesa; Ayala, Pedrod; Díaz-Araya, Guillermod; Godoy, Ivana; Chiong, Mariod; Lavandero, Sergiod,e; Jalil, Jorge E.a; Michea, Luisb,c


With regret, the published acknowledgements were incomplete [1]. The complete acknowledgments are as follows:

This work was supported by CONICYT/FONDECYT/REGULAR/N°1100874 to M.P.O, FONDEF D11I1122 to M.P.O., J.E.J., M.C., S.L., L.M. CONICYT/FONDECYT/REGULAR/N°1130550, CONICYT ANILLO ACT-71, Millenium Institute on Immunology and Immunotherapy (no. P09/016-F), to LM and ANILLO ACT 1111 and FONDAP 15130011 to S.L., L.G., M.C. C.M. holds a PhD fellowship from CONICYT, Chile.

Journal of Hypertension. 32(6):1354, June 2014.

doi: 10.1097/HJH.0000000000000094
ORIGINAL PAPERS: Pathophysiological aspects

Background: Little is known about the biological effects of angiotensin-(1–9), but available evidence shows that angiotensin-(1–9) has beneficial effects in preventing/ameliorating cardiovascular remodeling.

Objective: In this study, we evaluated whether angiotensin-(1–9) decreases hypertension and reverses experimental cardiovascular damage in the rat.

Methods and results: Angiotensin-(1–9) (600 ng/kg per min for 2 weeks) reduced already-established hypertension in rats with early high blood pressure induced by angiotensin II infusion or renal artery clipping. Angiotensin-(1–9) also improved cardiac (assessed by echocardiography) and endothelial function in small-diameter mesenteric arteries, cardiac and aortic wall hypertrophy, fibrosis, oxidative stress, collagen and transforming growth factor type β − 1 protein expression (assessed by western blot). The beneficial effect of angiotensin-(1–9) was blunted by coadministration of the angiotensin type 2(AT2) receptor blocker PD123319 (36 ng/kg per min) but not by coadministration of the Mas receptor blocker A779 (100 ng/kg per min). Angiotensin-(1–9) treatment also decreased circulating levels of Ang II, angiotensin-converting enzyme activity and oxidative stress in aorta and left ventricle. Whereas, Ang-(1–9) increased endothelial nitric oxide synthase mRNA levels in aorta as well as plasma nitrate levels.

Conclusion: Angiotensin-(1–9) reduces hypertension, ameliorates structural alterations (hypertrophy and fibrosis), oxidative stress in the heart and aorta and improves cardiac and endothelial function in hypertensive rats. These effects were mediated by the AT2 receptor but not by the angiotensin-(1–7)/Mas receptor axis.

aDivision de Enfermedades Cardiovasculares, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago

bMillennium Institute on Immunology and Immunotherapy

cInstituto de Ciencias Biomedicas, Facultad de Medicina, Santiago

dAdvanced Center for Chronic Diseases & Centro Estudios Moleculares de la Celula, Facultad Ciencias Quimicas y Farmaceuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile

eDepartment of Internal Medicine (Cardiology Division), University of Texas Southwestern Medical Center, Dallas, Texas, USA

Correspondence to María Paz Ocaranza, PhD, División de Enfermedades Cardiovasculares, Escuela de Medicina, Pontificia Universidad Católica de Chile, Marcoleta 391, Santiago 8330024, Chile. Tel: +562 2354 3407; fax: +562 2632 1924; e-mail:

Abbreviations: ACE2, angiotensin-converting enzyme 2; ACEIs, angiotensin-converting enzyme inhibitors; Ang, angiotensin; AT1R, angiotensin type 1 receptor; AT2R, angiotensin type 2 receptor; C, control rat; Cch, carbachol; EEL, external elastic lamina; eNOS, endothelial nitric oxide synthase; FBS, fetal bovine serum; FLVW, free left ventricular wall; IEL, internal elastic lamina; IVS, interventricular septum; L-NAME, N G-nitro-L-arginine methyl ester; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; RAS, renin–angiotensin system; RT-PCR, reverse transcription polymerase chain reaction; SHRSP, stroke-prone spontaneously hypertensive rats; TGF-β1, transforming growth factor type β1; αSMA, α-smooth muscle actin

Received 28 April, 2012

Accepted 27 November, 2013

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins